| Phone Icon 403.210.5275 | Email Icon Contact Us | Resize Text
Post Header Graphic

SU2C Announces $10 Million for Translational Cancer Research

Stand Up To Cancer (SU2C) is inviting proposals for a new $10 million Dream Team of top scientific investigators searching for new strategies to prevent or treat cancer, the American Association for Cancer Research (AACR), SU2C’s Scientific Partner, announced recently.

Unlike other Dream Team grants offered by SU2C in recent years that focused on specific types of cancer, such as colorectal cancer or lung cancer, the new $10 million grant is open to any type of translational cancer research.

“SU2C continues to seek solutions to a broad range of cancer problems,” said Phillip A. Sharp, PhD, chairman of the SU2C Scientific Advisory Committee, institute professor at MIT and its Koch Institute for Integrative Cancer Research, and Nobel laureate. “The door is open to bold new approaches to attack cancer, find new treatments, and bring new hope to patients.”

The SU2C Dream Team Translational Cancer Research Grant will fund a translational cancer research project that will address critical problems in patient care and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators, according to the “Call for Ideas” issued to the scientific community.

A Letter of Intent (LOI) must be submitted by noon U.S. Eastern time on Tuesday, Sept. 5, 2017.

Read more about the grant and the application requirements at the Stand Up To Cancer website.

SU2C Announces $10 Million for Translational Cancer Research

Listen Icon Listen to podcast